Irritable Bowel Syndrome is a gastrointestinal tract illness with the symptoms such as severe abdominal pain and alteration of bowel habits. Usually, the food passes through the intestinal tract and the movement of food is due to intestinal muscle contraction. But the IBS hampers natural movements of that muscle thus, food cannot pass through the digestive tract and may result in abdominal pain, mucus in the stool, diarrhoea, bloating and gas, constipation, and cramping. According to the Centers for Disease Control and Prevention (CDC) 2015, approximately 3 million people in the U.S. were reported being diagnosed with Irritable Bowel Syndrome.

Long tenure administration is essential to diagnose and treat IBS as it is a chronic disease condition. The IBS can be treated by making changes in daily diet, by reducing stress and lifestyle. Severe symptoms and signs of IBS can be detected in small groups of people who require treatment and counselling.

Drug launches and the strong pipeline with precise indication during the forecast period is expected to bolster the growth of global Irritable Bowel Syndrome (IBS) Treatment market.

According to International Foundation for Functional Gastrointestinal Disorders 2016, approximately 10-15% of the global population is affected by the irritable bowel syndrome. Moreover, women are more susceptible to have IBS than men. According to the International Foundation for Functional Gastrointestinal Disorders reports, 2 in 3 females are diagnosed to have IBS. This number is anticipated to increase during the upcoming period. In addition, according to the reports of Anxiety and Depression Association of America ratio of around one in five people in the U.S. are diagnosed to have irritable bowel syndrome. Imminent prevalence of people suffering IBS and the growing demand for the drugs to control the IBS is expected to form lucrative opportunities in this market. IBS shows a wide range of indications, thus, the cure is decided on the prevalence of the symptoms and drugs such as tricyclic antidepressants or antispasmodic agents are used.

The market for irritable bowel syndrome (IBS) treatment is perceiving remarkable significant growth due to the introduction of precise diagnosis standards and launch of novel therapeutic drugs classes by the key market players. Some of the USFDA approved drugs to control Irritable Bowel Syndrome (IBS) are Xifaxan (Rifaximin), Amitiza (Lubiprostone), Linzess (Linclotide), and Lotronex (Alosetron).

However, there is no such treatment that can treat the IBS completely. Thus, lack of straightforward treatment to cure the syndrome may hamper the market growth. Moreover, rising number of players and competition due to generic drugs is also a factor restraining the market growth.

Global Irritable Bowel Syndrome (IBS) Treatment Market Taxonomy

The global Irritable Bowel Syndrome (IBS) Treatment market is segmented on the basis of medical condition, drug type, distribution channel, and geography.

On the basis of medical condition, the global Irritable Bowel Syndrome (IBS) Treatment market is segmented into:

• IBS - Diarrhea
• IBS - Constipation

On the basis of drug type, the market for global Irritable Bowel Syndrome (IBS) Treatment is segmented into:

• Ramosetron Hydrochloride
• Linaclotide
• Rifaximin
• Eluxadoline
• Lubiprostone
• Others

On the basis of distribution channel, the global Irritable Bowel Syndrome (IBS) Treatment market is segmented into:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Geographically, the global irritable bowel syndrome (IBS) treatment market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Favourable reimbursement policies and the increased government support is expected to boost the growth of Irritable Bowel Syndrome (IBS) Treatment Market in North America region.

On the basis of geography, the global irritable Syndrome (IBS) treatment market is dominated by North America, followed by Europe and Asia Pacific. Growing graph of people suffering IBS and the demand for drugs are driving factors for the market growth in North America region. Moreover, improving healthcare infrastructure, ample opportunities with favourable reimbursement policies, government support, and raised per head income in this region is anticipated to enhance the market in this region. However, Asia Pacific is anticipated to generate lucrative opportunities in IBS market. Rising government support and a huge growth in drug launches to control the IBS is one of the major factor enhancing the market in this region. In addition, Japan is working forward to develop as the largest market in the IBS treatment by developing novel drugs further enhancing the global Irritable Bowel Syndrome (IBS) Treatment market growth.

Key players in the global Irritable Bowel Syndrome (IBS) treatment market:

• Sucampo Pharmaceuticals, Inc.
• Valeant Pharmaceuticals International, Inc.
• Ardelyx, Inc.
• Novartis AG
• GlaxoSmithKline plc.
• Ironwood Pharmaceuticals, Inc.
• Allergan Plc.
• Lexicon Pharmaceuticals, Inc.
• Pfizer Inc.
• Astellas Pharma Inc.
• Ono Pharmaceutical Co., Ltd.
• Synergy Pharmaceuticals
• Takeda Pharmaceutical Company Ltd
• Abbot Laboratories